AR041273A1 - Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) - Google Patents
Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)Info
- Publication number
- AR041273A1 AR041273A1 ARP030103357A ARP030103357A AR041273A1 AR 041273 A1 AR041273 A1 AR 041273A1 AR P030103357 A ARP030103357 A AR P030103357A AR P030103357 A ARP030103357 A AR P030103357A AR 041273 A1 AR041273 A1 AR 041273A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- heteroaryl
- amino
- heterocyclyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000009618 Transforming Growth Factors Human genes 0.000 title 2
- 108010009583 Transforming Growth Factors Proteins 0.000 title 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 33
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 7
- -1 derivatives thereof Chemical class 0.000 abstract 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 3
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 2
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 150000003557 thiazoles Chemical class 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41212002P | 2002-09-18 | 2002-09-18 | |
| US47126503P | 2003-05-16 | 2003-05-16 | |
| US48458103P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041273A1 true AR041273A1 (es) | 2005-05-11 |
Family
ID=32034216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103357A AR041273A1 (es) | 2002-09-18 | 2003-09-16 | Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7273936B2 (https=) |
| EP (1) | EP1542994B1 (https=) |
| JP (1) | JP4518956B2 (https=) |
| KR (1) | KR20050057415A (https=) |
| CN (1) | CN1681810A (https=) |
| AP (1) | AP2005003261A0 (https=) |
| AR (1) | AR041273A1 (https=) |
| AT (1) | ATE430147T1 (https=) |
| AU (1) | AU2003256003A1 (https=) |
| BR (1) | BR0314383A (https=) |
| CA (1) | CA2499429C (https=) |
| CO (1) | CO5550473A2 (https=) |
| CR (1) | CR7743A (https=) |
| DE (1) | DE60327443D1 (https=) |
| EA (1) | EA200500354A1 (https=) |
| ES (1) | ES2323421T3 (https=) |
| HR (1) | HRP20050250A2 (https=) |
| IS (1) | IS7711A (https=) |
| MA (1) | MA27443A1 (https=) |
| MX (1) | MXPA05002332A (https=) |
| NO (1) | NO20051838L (https=) |
| OA (1) | OA12926A (https=) |
| PA (1) | PA8582701A1 (https=) |
| PE (1) | PE20040987A1 (https=) |
| PL (1) | PL375975A1 (https=) |
| TW (1) | TW200413362A (https=) |
| UY (1) | UY27978A1 (https=) |
| WO (1) | WO2004026863A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| JP4547271B2 (ja) * | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物 |
| HRP20050247A2 (en) * | 2002-09-18 | 2005-10-31 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| GB0313914D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
| SG155222A1 (en) * | 2004-08-13 | 2009-09-30 | Genentech Inc | Thiazole based inhibitors of atp-utilizing enzymes |
| WO2006028029A1 (ja) * | 2004-09-07 | 2006-03-16 | Sankyo Company, Limited | 置換ビフェニル誘導体 |
| CA2580857A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| AR051091A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| CA2580762A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| EP2289510A1 (en) | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| EP1807085B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| AU2006343359A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| WO2007070866A2 (en) * | 2005-12-16 | 2007-06-21 | Alcon, Inc. | Control of intraocular pressure using alk5 modulation agents |
| WO2008150827A1 (en) * | 2007-05-29 | 2008-12-11 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| WO2009111502A2 (en) | 2008-03-03 | 2009-09-11 | University Of Notre Dame Du Lac | Anti-cancer compounds, synthesis thereof, and methods of using same |
| AU2012203026B2 (en) * | 2008-03-21 | 2014-06-12 | Novartis Ag | Novel heterocyclic compounds and uses thereof |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8338604B2 (en) | 2008-06-20 | 2012-12-25 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| HRP20201384T1 (hr) | 2014-01-01 | 2020-11-27 | Medivation Technologies Llc | Spojevi i postupci njihove upotrebe |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN105585565B (zh) * | 2014-10-23 | 2019-10-01 | 中国医学科学院药物研究所 | 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途 |
| CN106243012A (zh) * | 2016-08-02 | 2016-12-21 | 北方民族大学 | 新型吲哚类衍生物及其制备方法 |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| IL271149B2 (en) * | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| CN112694477B (zh) * | 2019-10-22 | 2024-02-06 | 四川科伦博泰生物医药股份有限公司 | 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途 |
| EP4061352A4 (en) | 2019-11-19 | 2024-02-28 | Trevena, Inc. | COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS |
| CN115466260B (zh) * | 2022-09-06 | 2023-10-13 | 延边大学 | 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3486009T2 (de) | 1983-09-09 | 1993-04-15 | Takeda Chemical Industries Ltd | 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung. |
| GB9201692D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| EP0983260A2 (en) | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
| DE69821132T2 (de) | 1997-10-27 | 2004-10-21 | Takeda Chemical Industries Ltd | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes |
| DE60001229T2 (de) * | 1999-04-09 | 2003-10-30 | Smithkline Beecham Corp., Philadelphia | Triarylimidazole |
| EP1205478A4 (en) | 1999-08-06 | 2004-06-30 | Takeda Chemical Industries Ltd | P38MAP KINASE INHIBITORS |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| JP2004517068A (ja) | 2000-11-16 | 2004-06-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| WO2002062787A1 (en) | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| JPWO2002062775A1 (ja) | 2001-02-02 | 2004-06-10 | 山之内製薬株式会社 | ２−アシルアミノチアゾール誘導体又はその塩 |
| JP2004521915A (ja) | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Ｔｇｆ過剰発現に対するピラゾール誘導体 |
| GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| GB0102665D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| GB0102673D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| CA2450400A1 (en) | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2004013135A1 (en) | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| GB0217787D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | C ompounds |
| HRP20050247A2 (en) | 2002-09-18 | 2005-10-31 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| PL375973A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
| CA2497971A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
| JP4547271B2 (ja) | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物 |
-
2003
- 2003-09-08 MX MXPA05002332A patent/MXPA05002332A/es active IP Right Grant
- 2003-09-08 CN CNA038222205A patent/CN1681810A/zh active Pending
- 2003-09-08 HR HR20050250A patent/HRP20050250A2/xx not_active Application Discontinuation
- 2003-09-08 OA OA1200500075A patent/OA12926A/en unknown
- 2003-09-08 EP EP03797426A patent/EP1542994B1/en not_active Expired - Lifetime
- 2003-09-08 DE DE60327443T patent/DE60327443D1/de not_active Expired - Lifetime
- 2003-09-08 AT AT03797426T patent/ATE430147T1/de not_active IP Right Cessation
- 2003-09-08 AP AP2005003261A patent/AP2005003261A0/xx unknown
- 2003-09-08 ES ES03797426T patent/ES2323421T3/es not_active Expired - Lifetime
- 2003-09-08 BR BR0314383-0A patent/BR0314383A/pt not_active IP Right Cessation
- 2003-09-08 AU AU2003256003A patent/AU2003256003A1/en not_active Abandoned
- 2003-09-08 JP JP2004568899A patent/JP4518956B2/ja not_active Expired - Fee Related
- 2003-09-08 KR KR1020057004611A patent/KR20050057415A/ko not_active Ceased
- 2003-09-08 WO PCT/IB2003/003823 patent/WO2004026863A1/en not_active Ceased
- 2003-09-08 CA CA2499429A patent/CA2499429C/en not_active Expired - Fee Related
- 2003-09-08 PL PL03375975A patent/PL375975A1/xx not_active Application Discontinuation
- 2003-09-08 EA EA200500354A patent/EA200500354A1/ru unknown
- 2003-09-15 PA PA20038582701A patent/PA8582701A1/es unknown
- 2003-09-15 PE PE2003000939A patent/PE20040987A1/es not_active Application Discontinuation
- 2003-09-15 UY UY27978A patent/UY27978A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103357A patent/AR041273A1/es unknown
- 2003-09-17 US US10/667,187 patent/US7273936B2/en not_active Expired - Fee Related
- 2003-09-17 TW TW092125637A patent/TW200413362A/zh unknown
-
2005
- 2005-02-24 IS IS7711A patent/IS7711A/is unknown
- 2005-03-15 CR CR7743A patent/CR7743A/es not_active Application Discontinuation
- 2005-03-16 CO CO05024531A patent/CO5550473A2/es not_active Application Discontinuation
- 2005-03-18 MA MA28157A patent/MA27443A1/fr unknown
- 2005-04-15 NO NO20051838A patent/NO20051838L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IS7711A (is) | 2005-02-24 |
| PA8582701A1 (es) | 2004-04-23 |
| OA12926A (en) | 2006-10-13 |
| US7273936B2 (en) | 2007-09-25 |
| CA2499429C (en) | 2010-09-21 |
| NO20051838L (no) | 2005-04-15 |
| CA2499429A1 (en) | 2004-04-01 |
| ATE430147T1 (de) | 2009-05-15 |
| EP1542994B1 (en) | 2009-04-29 |
| TW200413362A (en) | 2004-08-01 |
| JP4518956B2 (ja) | 2010-08-04 |
| AU2003256003A1 (en) | 2004-04-08 |
| WO2004026863A8 (en) | 2005-04-21 |
| CR7743A (es) | 2005-06-15 |
| MA27443A1 (fr) | 2005-07-01 |
| CO5550473A2 (es) | 2005-08-31 |
| ES2323421T3 (es) | 2009-07-15 |
| WO2004026863A1 (en) | 2004-04-01 |
| UY27978A1 (es) | 2004-04-30 |
| BR0314383A (pt) | 2005-07-19 |
| DE60327443D1 (de) | 2009-06-10 |
| AP2005003261A0 (en) | 2005-03-31 |
| EP1542994A1 (en) | 2005-06-22 |
| PE20040987A1 (es) | 2004-12-27 |
| CN1681810A (zh) | 2005-10-12 |
| HRP20050250A2 (en) | 2005-10-31 |
| EA200500354A1 (ru) | 2005-10-27 |
| PL375975A1 (en) | 2005-12-12 |
| JP2006502235A (ja) | 2006-01-19 |
| MXPA05002332A (es) | 2005-06-08 |
| KR20050057415A (ko) | 2005-06-16 |
| US20040110797A1 (en) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041273A1 (es) | Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
| AR041276A1 (es) | Compuestos de triazol como inhibidores del factor crecimiento transformador (tgf) | |
| AR041274A1 (es) | Compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
| AR041275A1 (es) | Compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) y composicion farmaceutica | |
| AR041272A1 (es) | Compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) y composicion farmaceutica que los contiene | |
| AR043449A1 (es) | Compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
| RU2483072C2 (ru) | Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12 | |
| JP2006501181A5 (https=) | ||
| AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| EA200300104A1 (ru) | НОВАЯ γ КРИСТАЛЛИЧЕСКАЯ ФОРМА ТРЕТ-БУТИЛАМИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
| RU2343145C2 (ru) | Производные изоиндолина | |
| AR036906A1 (es) | Compuestos de imidazopiridin como moduladores del receptor 5-ht4 | |
| BR0108378A (pt) | Sal cristalino de um composto, composição farmacêutica, processo para a manufatura do dito sal, e, uso do mesmo | |
| EA200500846A1 (ru) | Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| EA200500814A1 (ru) | Производные пирролопиримидина | |
| BG93979A (bg) | Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им | |
| ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
| EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
| BR0108893B1 (pt) | composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos. | |
| CY1108295T1 (el) | Παραγωγα μονοσακχαριτη αβερμεκτινης τα οποια εχουν παρασιτοκτονες ιδιοτητες | |
| AR053180A1 (es) | Derivados de 2 - piridona, un metodo para su preparacion, composiciones farmaceuticas que los contienen, un procedimiento para la elaboracion de las mismas y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la neutrofilo elastasa (hne). | |
| EA200300982A1 (ru) | Гетероциклические производные для лечения рака и других пролиферативных заболеваний | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |